Zobrazeno 1 - 4
of 4
pro vyhledávání: '"E B Maĭkov"'
Autor:
E B Maĭkov, Iu A Iuricheva, N Iu Mironov, S F Sokolov, S P Golitsyn, L V Rozenshtraukh, E I Chazov
Publikováno v:
Терапевтический архив, Vol 87, Iss 1, Pp 38-48 (2015)
Aim. To evaluate the efficacy and safety of refralon (niferidil), a new class III antiarrhythmic agent whose activity is related to the block of delayed rectifying potassium current and to the prolongation of atrial and ventricular action potential a
Externí odkaz:
https://doaj.org/article/a061fcf2ee1442eebc93d2a1c3d4dd61
Autor:
N Iu, Mironov, S P, Golitsyn, S F, Sokolov, E B, Maĭkov, N B, Shlevkov, Iu A, Iuricheva, Iu V, Mareev, L V, Rosenshtraukh, E I, Chazov
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 75(10)
Intracardiac electrophysiological effects and antiarrhythmic activity of novel domestic class III antiarrhythmogenic drug niferidil has been studied in a group of 25 patients with paroxismal supraventricular tachycardia (PSVT) diagnosis. The drug was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bc71560e7881b7b5961817a55e7ee410
https://pubmed.ncbi.nlm.nih.gov/23240154
https://pubmed.ncbi.nlm.nih.gov/23240154
Autor:
E B, Maĭkov
Publikováno v:
Kardiologiia. 52(11)
Last two decades have been dedicated to intensive search for new class III antiarrhythmic drugs, especially for atrial fibrillation. Here we present a review of the status this problem. Influence on transmembranous ion currents and mechanisms of anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::58239d26194f8a65a89ce1f8f42912af
https://pubmed.ncbi.nlm.nih.gov/23237397
https://pubmed.ncbi.nlm.nih.gov/23237397
Autor:
Iu A, Iuricheva, E B, Maĭkov, S F, Sokolov, Iu L, Klimenko, T L, Kratskina, G S, Tarasovskiĭ, O A, Bil'dinov, S A, Bakalov, S P, Golitsyn, G G, Beloshapko, A V, Iushmanova, L V, Rozenshtraukh, E I, Chazov
Publikováno v:
Kardiologiia. 51(1)
The aim of the study was to evaluate the efficacy and safety of administered intravenously niferidil in doses 10, 20 and 30 mkg per kg in patients with persistent atrial fibrillation (AF) and flutter (AFL) for pharmacological cardioversion. The study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::69582e54b6477f1031d8ce65fa7e82d7
https://pubmed.ncbi.nlm.nih.gov/21626804
https://pubmed.ncbi.nlm.nih.gov/21626804